News

Message from our Suppliers

 

Lexogen:

Lexogen is committed to continue its operations and is taking sensible precautions to minimize any potential impact of COVID-19 to our employees and our customers.

As product security and product quality are our biggest concerns, we are further tightening our already stringent working conditions, that our personnel normally follow in an RNA products focused company.

 

In the given situation, we are particularly engaged to maintain supply continuity, by implementing specific measures to minimize any disruption risks:

 

•             Increased levels of hygiene

•             Global required work from home policy for those whose work is not on site critical.

•             Reduced travel

•             Increased stock of products at all our warehouses

 

Effective immediately we are suspending production of trial kits, to focus our efforts on supplying the increased demand on our full products.

 

As the situation might change any moment, we want to be able to supply our products to meet any higher demands from our customers all over the world.

Being an RNA-focused company, we know that our products are central to understanding the disease and support researchers who are fighting against it.

With my best regards,

 

Dr. Paolo Marcandalli
Sr. Manager Global Distributor Sales

 




Mission Bio:

While the climate around COVID-19 remains uncertain, we know that your work to help develop treatments and cures for cancer won’t stop. And we won’t either. We at Mission Bio want to let you know that we are committed to supporting you and your critical cancer research, so we will be hosting some virtual events in the coming weeks:

 

 

    • How to design a custom panel using Tapestri Designer
    • How to run an analysis for DNA+protein experiments with pipeline and other workflows
    • How to visualize your data using Tapestri Insights
    • And more!

 

  • Journal Clubs:The adoption of single-cell science is real, and there have been some exciting manuscripts recently published that build on the excitement and utility of single-cell genomics. We also have presented posters and workshops at conferences like AGBT and ABRF. In case you missed them, we will host journal club sessions to review these scientific presentations, some even with the authors themselves!

To keep up with the calendar of our virtual sessions, please, email info@d-markbio.com or follow us on LinkedIn, Twitter or Facebook. 

 

Thank you for choosing Mission Bio as a partner to help you advance precision medicine. We wish the very best for you and your families.

Best,
Charlie Silver
CEO, Mission Bio

 


 

LGC:

Dear Customer:

LGC’s Clinical Diagnostics Business Unit (Maine Standards and SeraCare Life Sciences), in coordination with our parent and

sister companies, is following the COVID-19 outbreak and is closely monitoring information available from the World Health

Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).

Our three sites in Massachusetts, Maryland and Maine maintain a robust Business Continuity & Disaster Recovery (BCDR)

protocol and system of readiness. This includes coordination with our corporate Enterprise Risk Management (ERM) team to

perform regular, mock desktop exercises to prepare for scenarios such as this. Importantly, we leverage the learnings from the

40+ sites within LGC’s family of companies and deploy them locally, as appropriate, within our business unit.

Our management team has reviewed these BCDR polices and made appropriate adjustments following the public health

guidance available to date. We have proactively taken steps to both ensure the safety of our employees and the security of our

supply chain and will continue to commit the necessary resourcing provisions to meet these obligations.

Key measures that we have now implemented include:

HEALTH & SAFETY

Employees have been trained on personal preventative health measures. Public health posters, with reminders of proper

techniques for things such as handwashing, etc. are posted in all facilities. Daily cleaning protocols have been enhanced.

Access to all facilities has been limited to LGC staff, except where required for equipment and other maintenance. When

permitted, incoming service providers are required to follow internal prevention procedures.

TRAVEL

Since the end of January, all business travel by employees either to, from or transitioning through China and Hong Kong

has been prohibited. This policy is monitored and reviewed for other areas of the world where there are significant outbreaks.

Domestic US travel is reviewed and approved only on an as needed basis.

Attendance at all tradeshows and other large gatherings of people is being reviewed and subsequently limited, avoided or

cancelled.

BUSINESS CONTINUITY

Our Planning and Procurement Team has completed a review of inventory stocking levels and has verified adequate

supplies of finished products, intermediates, safety stocks and raw materials.

Likewise, we are in-process on surveying our suppliers to re-assess their preparedness with respect to our supply chain

needs. Consistent with pre-existing policy and where available, multiple suppliers are qualified for critical raw materials.

To be proactive, and where appropriate, additional provisioning of production materials is underway. Our production

schedule and capacity remain under regular review and at this time, we expect no interruption to our delivery commitments.

Our decentralized order processing and logistics model, together with our shared ERP and other business applications,

affords us, if and as needed, the ability to work remotely, and from our various sites.

We are constantly reviewing our approach to business resilience through updated internal processes and procedures across

our sites and we continue to monitor guidance provided by the relevant health and safety authorities. We will provide updates to

our customers should the need arise. Please reach out to your account representative if you have any questions.

Respectfully,

Michael Sweatt

Executive Vice President

Dear Customers and Distributors,

LGC’s Clinical Diagnostics Business Unit (Maine Standards and SeraCare Life Sciences), in coordination with our parent and

sister companies, is following the COVID-19 outbreak and is closely monitoring information available from the World Health

Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).

Our three sites in Massachusetts, Maryland and Maine maintain a robust Business Continuity & Disaster Recovery (BCDR)

protocol and system of readiness. This includes coordination with our corporate Enterprise Risk Management (ERM) team to

perform regular, mock desktop exercises to prepare for scenarios such as this. Importantly, we leverage the learnings from the

40+ sites within LGC’s family of companies and deploy them locally, as appropriate, within our business unit.

Our management team has reviewed these BCDR polices and made appropriate adjustments following the public health

guidance available to date. We have proactively taken steps to both ensure the safety of our employees and the security of our

supply chain and will continue to commit the necessary resourcing provisions to meet these obligations. The attached memo

further delineates the actions that we have been taking to address overall Supply Chain Continuity.

As this outbreak evolves, and in light of recent government responses related to travel, this update is intended to specifically

address our actions and position related to outgoing shipments to our customers and distributors, and our ability to move product

from our facilities to you.

Our Logistics team has reached out to each of the carriers that we use, including major carriers (i.e. FedEx, UPS, DHL), as well

as our freight forwarders. The common message that we have received is:

· The current travels ban that impact commercial passenger travel do not prohibit cross-border cargo movement. Carriers

have not experienced any cancellations of scheduled shipments.

· Given that some cargo travels within commercial passenger modes of transport, and many of these routes are being limited

or restricted, cargo is being re-routed through traditional cargo transportation routes. This adds significant volume to those

means of transport and delays are to be expected.

As a result, we are proactively working with each of our carriers to schedule shipments farther in advance in order to ensure that

our shipments are at the head of the delivery queue and that we can provide as much advanced notice of potential delays as

possible.

Where we utilize freight forwarders specified and coordinated directly by a customer, our logistics team will be reaching out to

you directly to coordinate communication with these forwarders, again with the intent of providing and receiving advance notice

to ensure successful order fulfilment.

Because this is a fluid and rapidly evolving situation, to mitigate potential delays and provide us with as much visibility as possible,

we encourage you to submit your orders in advance of demand to help us ensure your ongoing supply chain continuity.

We appreciate your continued business, and we will continue to monitor the situation and provide further updates as needed.

Sincerely,

Todd Anderson

Vice President, Supply Chain


 

Macherey-Nagel:

.Dear valued customers and business partners,

The current situation poses an unprecedented challenge to all of us.

In order to reliably maintain our usual standard of service while ensuring the safety of our staff, customers and suppliers, MACHEREY-NAGEL has implemented the following extensive technical and organizational measures: We have put all nonessential customer visits on hold for the time being. We have reorganized our workplaces in a manner that minimizes direct physical contact between employees. Production at our site in Düren takes place in separate shifts. Furthermore, additional hygiene measures have been implemented in all areas of our company.

Having put these measures in place, we are actually confident that we will continue to be able to complete all our orders and to honor delivery times in order to supply you with all of the products required for your analysis or production. Our sales and support teams remain fully operational. You can reach your contact persons under their regular telephone numbers and email addresses.

Please stay healthy and let’s overcome the current challenges together.

You can always rely on MACHEREY-NAGEL even in difficult times.

Best wishes,
your MACHEREY-NAGEL team.


PCR Bio:

We are living in unprecedented times, and as the response to the COVID-19 pandemic evolves, we wanted to advise you on how we are addressing this situation at PCR Biosystems. 
 
Our top priorities are the safety and well-being of our employees and the uninterrupted supply of our reagents to customers around the world. We are committed to ensuring researchers and organisations in all markets can access the PCR products and services they need. 

This week we have implemented shift-based working for production, assembly and order fulfilment. We have 3 detached teams working 7 days a week, with 2 fully trained commercial teams in reserve to provide operational support if required. We are working closely with our customers, partners and suppliers, and we are ready to implement further contingency plans if necessary to ensure we continue to meet demand.

Of crucial importance are the needs of our diagnostic partners - including laboratory and hospital customers - in testing for SARS-CoV-2 on a vast scale. To meet these needs and provide supply chain security we have massively increased manufacture of qPCRBIO Probe 1-Step Go and all other critical reagents for rapid and sensitive RT-qPCR. 

We are ready and able to supply you, and we will do all we can to support the scientific effort in responding to COVID-19.

For further information, including large sample packs and technical advice, please get in touch by emailing info@d-markbio.com or call us on
416-297-8220

With best wishes, 

The PCRBIO Team